LCTX Quote, Financials, Valuation and Earnings

Belite Bio, Inc. has a net margin of -808.26% compared to Lineage Cell Therapeutics, Inc.'s net margin of --. Lineage Cell Therapeutics, Inc.'s return on equity of -117.46% beat Belite Bio, Inc.'s return on equity of -37.13%.

Lineage Cell Therapeutics, Inc. has a consensus price target of $4.17, signalling upside risk potential of 152.53%. On the other hand Belite Bio, Inc. has an analysts' consensus of $184.33 which suggests that it could grow by 18.98%. Given that Lineage Cell Therapeutics, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Lineage Cell Therapeutics, Inc. is more attractive than Belite Bio, Inc..

Lineage Cell Therapeutics, Inc. has a beta of 1.776, which suggesting that the stock is 77.601% more volatile than S&P 500. In comparison Belite Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lineage Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Belite Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics, Inc. pays -- of its earnings as a dividend. Belite Bio, Inc. pays out -- of its earnings as a dividend.

Lineage Cell Therapeutics, Inc. quarterly revenues are $3.7M, which are larger than Belite Bio, Inc. quarterly revenues of --. Lineage Cell Therapeutics, Inc.'s net income of -$29.8M is lower than Belite Bio, Inc.'s net income of -$21.7M. Notably, Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while Belite Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics, Inc. is 34.46x versus -- for Belite Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -808.26% compared to Lineage Cell Therapeutics, Inc.'s net margin of --. Lineage Cell Therapeutics, Inc.'s return on equity of -117.46% beat CEL-SCI Corp.'s return on equity of -266.61%.

Lineage Cell Therapeutics, Inc. has a consensus price target of $4.17, signalling upside risk potential of 152.53%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 802.34%. Given that CEL-SCI Corp. has higher upside potential than Lineage Cell Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Lineage Cell Therapeutics, Inc..

Lineage Cell Therapeutics, Inc. has a beta of 1.776, which suggesting that the stock is 77.601% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Lineage Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Lineage Cell Therapeutics, Inc. quarterly revenues are $3.7M, which are larger than CEL-SCI Corp. quarterly revenues of --. Lineage Cell Therapeutics, Inc.'s net income of -$29.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics, Inc. is 34.46x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -808.26% compared to Lineage Cell Therapeutics, Inc.'s net margin of -1144.46%. Lineage Cell Therapeutics, Inc.'s return on equity of -117.46% beat Ocugen, Inc.'s return on equity of -345.08%.

Lineage Cell Therapeutics, Inc. has a consensus price target of $4.17, signalling upside risk potential of 152.53%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 538.3%. Given that Ocugen, Inc. has higher upside potential than Lineage Cell Therapeutics, Inc., analysts believe Ocugen, Inc. is more attractive than Lineage Cell Therapeutics, Inc..

Lineage Cell Therapeutics, Inc. has a beta of 1.776, which suggesting that the stock is 77.601% more volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 4.540, suggesting its more volatile than the S&P 500 by 354.007%.

Lineage Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Lineage Cell Therapeutics, Inc. quarterly revenues are $3.7M, which are larger than Ocugen, Inc. quarterly revenues of $1.8M. Lineage Cell Therapeutics, Inc.'s net income of -$29.8M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics, Inc. is 34.46x versus 77.39x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ProKidney Corp. has a net margin of -808.26% compared to Lineage Cell Therapeutics, Inc.'s net margin of -16517.51%. Lineage Cell Therapeutics, Inc.'s return on equity of -117.46% beat ProKidney Corp.'s return on equity of -42.51%.

Lineage Cell Therapeutics, Inc. has a consensus price target of $4.17, signalling upside risk potential of 152.53%. On the other hand ProKidney Corp. has an analysts' consensus of $6.50 which suggests that it could grow by 156.92%. Given that ProKidney Corp. has higher upside potential than Lineage Cell Therapeutics, Inc., analysts believe ProKidney Corp. is more attractive than Lineage Cell Therapeutics, Inc..

Lineage Cell Therapeutics, Inc. has a beta of 1.776, which suggesting that the stock is 77.601% more volatile than S&P 500. In comparison ProKidney Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lineage Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProKidney Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics, Inc. pays -- of its earnings as a dividend. ProKidney Corp. pays out -- of its earnings as a dividend.

Lineage Cell Therapeutics, Inc. quarterly revenues are $3.7M, which are larger than ProKidney Corp. quarterly revenues of $217K. Lineage Cell Therapeutics, Inc.'s net income of -$29.8M is higher than ProKidney Corp.'s net income of -$35.8M. Notably, Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while ProKidney Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics, Inc. is 34.46x versus 444.41x for ProKidney Corp.. Usually stocks with elevated PS ratios are considered overvalued.